|
Found 78 result(s) FROM 1963 pages containing the term 'biomarker'.
Wednesday Oct 14, 2009
Research Breakthrough: Common Retrovirus May Cause CFS
Two-thirds of chronic fatigue syndrome patients carry xenotropic murine leukemia virus-related virus (XMRV) in their blood...
Monday Sep 21, 2009
RA Gene Screening Almost Ready for Primetime
Genetic screening for rheumatoid arthritis risk is not yet clinically useful, but combining five confirmed RA loci may provide an accurate predictive test...
Thursday Jul 16, 2009
Array BioPharma Stops Work on ARRY-797 Pan-Cytokine Inhibitor for RA Despite Good Early Data
The pan-cytokine inhibitor ARRY-797 was safe at doses of up to 1,200 mg/day in a phase 1 dose-escalation study in RA patients, but will not be developed further for use in RA...
Thursday Jun 25, 2009
From Inflammation to Bone Formation in SpA
Clinical and animal data reported at EULAR suggest that both controlling inflammation and preventing new bone formation may be required to stop ankylosing spondylitis progression...
Thursday May 14, 2009
Could a Urine Test Identify Early OA?
Separate sets of collagen degradation markers can differentiate very early knee OA from knee pain that is not due to OA...
Friday Apr 17, 2009
Naltrexone May Offer Low-Cost Help for Fibromyalgia
Low doses of naltrexone provided significant pain relief in a pilot study in fibromyalgia...
Wednesday Mar 11, 2009
Biomarkers Are Red Flag for Rheumatoid Arthritis Risk
A soluble TNF receptor begins to increase many years before RA becomes clinically symptomatic and might make a useful screening tool to identify those at risk...
Wednesday Nov 12, 2008
Novartis’ ACZ885 Phase III Data Show Rapid, Sustained Clinical Remission in Children and Adults with CAPS, a Group of Rare, Potentially Life-Threatening Autoinflammatory Diseases
Novartis also announced that preliminary results of a phase I/II study in systemic juvenile idiopathic arthritis showed that most patients treated with ACZ885 achieved substantial clinical improvement within 15 days...
Tuesday Oct 28, 2008
Syk Kinase Inhibitor R788 (Tamatinib fosdium) Achieves ACR20 Response Rates Over 60% in Phase II Trial
The oral Syk kinase inhibitor R788 achieved impressive efficacy in a phase II RA trial...
Wednesday Oct 08, 2008
Fractalkine May Be Key to Unleashed Immune Response in Rheumatoid Arthritis
Fractalkine (FKN) is emerging as a central player in the RA synovial inflammation, neovascularization, and joint destruction, and also might be link between joint damage and increased cardiovascular risk...
Tuesday Sep 30, 2008
Microparticles May Be Big Players in Systemic Scleroderma Disease Activity
Microparticles—small, membrane, coated vesicles—found in the blood of systemic scleroderma patients might not be inert debris…
Friday Jul 25, 2008
New High-Resolution Device Aids Finger MRI in Scleroderma
High-resolution magnetic resonance angiography (micro-MRA) can readily measure vascular disease of fingers in systemic sclerosis…
Monday Jun 02, 2008
Osteologix Reports Additional Positive Phase II Data for NB S101 (strontium malonate) for Osteoporosis
Osteologix reported that the osteoporosis drug candidate was well-tolerated and significantly suppressed bone resorption while simultaneously improving bone mineral density (BMD) at 12 weeks...
Tuesday May 13, 2008
Osteologix’s IND for NB S101 (strontium malonate) to Treat Osteoporosis Accepted by US FDA
The US FDA has accepted Osteologix's IND application for NB S101 (strontium malonate), a dual-acting bone agent, to treat and prevent osteoporosis...
Thursday Feb 28, 2008
Acceleron, Celgene to Collaborate on Anabolic Bone Agent ACE-011, a Decoy Activin Receptor, for Cancer-Related Bone Loss
Acceleron Pharma and Celgene Corp announced a worldwide strategic collaboration for the development and commercialization of ACE-011, a novel bone-forming compound for the treatment of cancer-related bone loss...
Thursday Dec 20, 2007
New EULAR Recommendations on Systemic Glucocorticoids Stress Monitoring for Adverse Events
EULAR has issued new evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases...
Thursday Dec 13, 2007
MRI Bone Edema Shows Differences, Similarities in RA and OA
MRI bone edema predicts radiographic progression in RA and correlates with pain in OA...
Thursday Nov 08, 2007
Serum Uric Acid May Be Independent Risk Factor in RA Cardiovascular Disease
Elevated serum uric acid, a potentially modifiable problem, may be an independent risk factor for cardiovascular disease in patients with RA...
Thursday Nov 08, 2007
Biomarkers May Identify Risk for Preeclampsia in Lupus Pregnancies
Measuring levels of circulating antiangiogenic factors sFlt-1 and sEng may help identify which patients with systemic lupus erythematosus (SLE) and/or antiphospholipid antibodies will develop preeclampsia...
Wednesday Nov 07, 2007
Osteologix Reports Osteoporosis Phase II Trial of Strontium Malonate Meets Primary Endpoint
Osteologix, Inc, a specialty biopharmaceutical company targeting musculoskeletal diseases, announced positive top-line results of an international, randomized, double-blind, active-controlled phase II dose-response of its lead investigational drug, strontium malonate (NB S101) for osteoporosis...
Wednesday Sep 26, 2007
Wanted: Lupus Patients for Clinical Trials
The lupus therapeutic landscape is changing slowly but dramatically, and more patients are needed to help speed the development of new drugs…
Thursday Aug 09, 2007
Calcitonin Study Heightens Interest in Antiresorptive Agents to Prevent OA Joint Damage
Calcitonin prevents the development of OA in an animal model and adds to evidence that antiresorptive agents can protect both cartilage and bone...
Thursday Jul 19, 2007
ACR REF Campaign Taps Brightest Minds to Cure RA
The American College of Rheumatology Research and Education Foundation has awarded $6 million in grant money to 15 arthritis researchers as part of a new "Within Our Reach: Finding a Cure for Rheumatoid Arthritis" campaign.
Friday Jun 22, 2007
Belimumab Improves Symptoms in Nearly Half of Lupus Patients at 52 Weeks, Advances to Phase III Studies
Belimumab produces sustained improvement in SLE symptoms…
Thursday Jun 14, 2007
More Patients Needed to Validate Biomarkers and Genotyping in Rheumatoid Diseases
Biomarkers and genotyping technology have outpaced the number of patient cohorts available for validation studies in rheumatoid diseases, but the new approaches are expected to change how clinicians assess disease susceptibility and predict response to therapy...
Monday Apr 23, 2007
Current Viewpoints
CIAOMed Roundtable: Lupus Experts Predict More Use of RA Drugs, Seek Biomarkers to Speed Clinical Trials
Decades have passed since the last FDA approval of a new drug for lupus, but CIAOMed's "Virtual Roundtable" of lupus experts expect major gains from drugs adopted recently from RA treatment and they hope for promising advances from research consortia seeking lupus biomarkers...
Wednesday Apr 11, 2007
La Jolla Pharmaceutical Company to Net Approximately $38 Million in Public Offering
La Jolla Pharmaceutical Company, a clinical-stage pharmaceutical company focused on autoimmune and inflammatory disorders, announced the receipt of estimated aggregate net proceeds of approximately $38 million from the recently completed underwritten public offering of 5,800,000 shares of its common stock, including the expected proceeds from an exercised overallotment option to the underwriters to purchase an additional 870,000 shares...
Wednesday Apr 04, 2007
Repeated B-Cell Depletion Safe, Effective Over 5 Years in RA
B-cell depletion with rituximab was effective for an average of 15 months per cycle and was relatively well tolerated for up to 5 repeat cycles in patients with otherwise refractory RA...
Monday Mar 19, 2007
Medivir Begins Initial Clinical Trial of Osteoporosis Drug Cathepsin K Inhibitor
Medivir AB, a clinical-stage pharmaceutical company, announced the start of its first osteoporosis clinical trial of MIV-701, an orally bioavailable inhibitor of cathepsin K, a thiol (cysteine) protease that is expressed by osteoclasts and degrades key bone and cartilage matrix proteins, including type 1 collagen...
Thursday Mar 15, 2007
MIC-1 May Be a Biomarker for Erosive Disease in RA
Serum levels of the transforming growth factor ß superfamily member MIC-1 may help clinicians identify rheumatoid arthritis patients who are at greatest risk for erosive disease and thus are candidates for aggressive therapy…
Friday Mar 09, 2007
La Jolla Pharmaceutical Reports Positive Interim Antibody Results From Riquent® Lupus Phase III Trial; Results Imply Greater Probability of Clinical Benefit in the Treatment of Lupus Renal Disease as a Trial Outcome
La Jolla Pharmaceutical Company, a clinical-stage pharmaceutical company focused on autoimmune and inflammatory disorders, announced positive interim antibody results from its ongoing double-blind, placebo-controlled randomized phase III trial of Riquent® (abetimus sodium), its drug candidate for the treatment of renal disease in patients with systemic lupus erythematosus (SLE).
Wednesday Feb 21, 2007
XDx Partners with the University of Minnesota and the Feinstein Institute to Develop Molecular Diagnostics to Improve the Clinical Management of Lupus
XDx Inc, a molecular diagnostics company that focuses on immune-mediated diseases, announced the signing of an agreement with the University of Minnesota to exclusively license key intellectual property assets in the field of systemic lupus erythematosus (SLE).
Thursday Jan 18, 2007
New Treatments Rocked Rheumatology in 2006
New treatment options have advanced rheumatology care in 2006, but lupus remains an unsolved problem, and CIAOMed Editorial Board members expect economic issues to greatly impact rheumatology practice in 2007...
Wednesday Dec 06, 2006
Serum MMP-3 May Be Biomarker of Joint Damage in AS, MRI Accuracy Questioned
Measuring serum levels of metalloproteinase 3 (MMP3) may be an inexpensive yet accurate way for rheumatologists to predict which AS patients will develop joint damage, particularly in those with pre-existing radiographic damage...
Tuesday Dec 05, 2006
Nastech, P&G Amend Agreement for Development of Parathyroid Hormone (PTH1-34) Nasal Spray for Treatment of Osteoporosis
Nastech Pharmaceutical Company Inc (BOTHELL, Washington) announced the amendment of its previous agreement with Procter & Gamble Pharmaceuticals, Inc (P&G) for the clinical development program of the parathyroid hormone (PTH1-34) nasal spray for the treatment of osteoporosis. The amendment includes an additional phase II dose ranging study as well as a change in the timing of payments.
Wednesday Nov 29, 2006
Source MDx Awarded SBIR Phase I Grant; Will Collaborate with Tufts-New England Medical Center to Develop Biomarkers to Predict Responders and Nonresponders to Anti-TNF Therapy for Rheumatoid Arthritis
Source MDx, a molecular diagnostics company, and Tufts-New England Medical Center (NEMC) announced a collaboration to investigate the clinical use of RNA-based molecular diagnostic tests to monitor rheumatoid arthritis (RA) disease status and response to therapy.
Wednesday Nov 15, 2006
FDA's Woodcock Pushes for Biomarkers as Key to New Drug Development and Improving Drug Safety
Janet Woodcock, MD, the FDA's deputy chief for operations, speaking at the American College of Rheumatology meeting, said that the 1990s era of blockbuster drugs is over, and that a fast public/private collaboration to identify biomarkers that permit drug researchers to "move beyond demographics" is needed to get new drug development moving and to improve drug safety... ACR 2006 Meeting.
Tuesday Nov 14, 2006
PROMPT Study Shows "Window of Opportunity" in Early Undifferentiated Arthritis
Early MTX treatment can delay and possibly prevent progression to RA among anti-CCP positive patients who have early, undifferentiated arthritis... van Dongen H, et al. Presented at: ACR 2006 Meeting.
Monday Nov 13, 2006
Biomarkers Might Be Modifiable Risk Factors for RA
Autoantibodies may lead to risk reduction strategies for preventing RA... Holers VM. Presented at ACR 2006 Meeting.
Wednesday Nov 08, 2006
Steroids May Prevent Lupus Flares in Some Patients with Stable SLE
Intervening with moderate doses of steroids can prevent lupus flares in the subgroup of patients with stable disease but rising anti-dsDNA and C3 levels...
Monday Nov 06, 2006
Array BioPharma Reports Success in Two Approaches to Inflammatory Disease: MEK Inhibitor Achieves Phase I Clinical Objectives; p38 MAP Kinase Inhibitor Advances into Clinical Development
Array BioPharma Inc. (BOULDER, Colorado), a biopharmaceutical company focused on the discovery, development, and commercialization of orally active, small molecule drugs for the treatment of inflammatory diseases and cancer, announced preliminary results from a phase I clinical trial evaluating its first-in-class MEK (MAPK kinase) inhibitor for the treatment of inflammatory diseases.
Monday Oct 16, 2006
La Jolla Pharmaceutical Withdraws Marketing Authorization Application for Riquent in Europe
La Jolla Pharmaceutical Company announced that it has requested the withdrawal of its Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for Riquent® (abetimus sodium), the company's drug candidate for lupus renal disease...
Monday Oct 02, 2006
La Jolla Pharmaceutical to Expand Number of Clinical Trial Sites for Its Phase III International Trial of Riquent for the Treatment of Lupus Renal Disease
La Jolla Pharmaceutical Company (SAN DIEGO, Calif.), a biotechnology company developing therapeutics for antibody-mediated autoimmune diseases and inflammation, announced progress and the expansion of its phase III trial of Riquent® (abetimus sodium, previously referred to as LJP 394) for the treatment of lupus renal disease, a leading cause of sickness and death in patients with lupus.
Monday Aug 14, 2006
Lower IL-4, IL-10 Levels Seen as Possible Basis for Fibromyalgia Test
New research showing that patients with chronic widespread pain have significantly lower levels of the anti-inflammatory cytokines Interleukin (IL)-4 and IL-10 may help doctors develop a cytokine expression profile that can aid in the diagnosis of fibromyalgia. Üçeyler, N, et al. Arthritis Rheum. 2006;54:2656-2664
Thursday Aug 10, 2006
Michigan Researchers to Study ACL Injuries, Bone Bruises, in Knee OA
Anterior cruciate ligament (ACL) injuries are common in young athletes and often lead to later knee osteoarthritis (OA). A new prospective study will try to determine whether bone bruises add to that risk.
Monday Jul 24, 2006
RA Patients with Persistently High ESR Rate at Greater Risk for Heart Failure
Rheumatoid arthritis with persistently elevated erythrocyte sedimentation rate values are at especially high risk of heart failure and should be monitored accordingly... Maradit-Kremers H, et al. Ann Rheum Dis. Published Online First: 3 July 2006. doi:10.1136/ard.2006.053710
Monday Jun 19, 2006
PDL's Nuvion® Humanized Anti-CD3 T-Cell Receptor Antibody Active in Crohn's Disease, Ulcerative Colitis
PDL BioPharma, Inc, of Fremont, California, announced that new data from studies of Nuvion® (visilizumab, a humanized low FcR-binding IgG2 anti-CD3 monoclonal antibody) in Crohn's disease and ulcerative colitis were presented at the annual Digestive Disease Week meeting...
Monday Jun 12, 2006
Low-Carb Diets Do Not Cheat Bones
Researchers had suspected that low-carbohydrate diets would increase bone turnover, compromise bone quality, and lead to osteoporosis, but a new study suggests that such diets do no such thing... Carter JD, et al. Osteoporos Int. In press.
Wednesday May 31, 2006
British Clinicians Challenge Restrictive TNF Inhibitor Guidelines
British guidelines for the use of TNF inhibitors are unduly restrictive and should be revised, practitioners charge... Deighton CM, et al. Rheumatology. 2006;45:649-652.
Wednesday May 31, 2006
Synta Initiates Phase II Clinical Trials in RA, CVID for Oral Inhibitor of IL-12 and IL-23
Synta Pharmaceuticals Corp announced the dosing of the first patients in its phase IIa clinical studies of apilimod mesylate in RA and CVID...
Friday Apr 14, 2006
Testing for Second-Generation Anti-CCP Antibodies in Patients With Early RA is Useful for Predicting Radiographic and Functional Outcomes
Anti-CCP antibodies are a useful diagnostic tool, particularly among seronegative rheumatoid arthritis (RA) patients. The presence of anti-CCP antibodies confers prognostic utility for radiographic and functional outcomes... Quinn MA, et al. Rheumatology. 2005;45:478-480.
Monday Apr 03, 2006
TransPharma Medicalâ„¢ Ltd Gains Promising Clinical Trial Results for Its hPTH (1-34) Transdermal Delivery, Investigative Product for Osteoporosis
TransPharma Medicalâ„¢ Ltd, of Lod, Israel, announced promising results from the first human clinical trials demonstrating transdermal delivery of human parathyroid hormone 1-34 fragment (hPTH 1-34)...
Thursday Mar 23, 2006
Biomarkers May Identify Early Implant Failure or Loosening
New research is helping to identify early biomarkers of prosthetic performance as well as genetic polymorphisms that predict risk of osteolysis... Presented at: 52nd Annual Meeting of the Orthopaedic Research Society; March 18–22, 2006; Chicago, Ill.
Wednesday Mar 01, 2006
Biosystems International Collaborates in Two Biomarker Programs
BioSystems International, of Evry, France, announced a collaborative agreement with AstraZeneca...
Thursday Jan 19, 2006
Biomarkers Help Predict OA Patients at Greatest Risk of Progression
A single measurement of serum hyaluronic acid or short-term changes in urine C-telopeptide of type II collagen can identify osteoarthritis patients at the greatest risk of disease progression... Bruyere O, et al. Ann Rheum Dis. Published online January 5, 2006; doi:10.1136/ard.2005.045914.
Tuesday Jan 17, 2006
Timely ET May Help Stave Off Cartilage Degradation in Osteoarthritis
Estrogen therapy initiated immediately following ovariectomy staves off the cartilage loss known to accompany menopause... Oestergaard S, et al. Presented at: 10th World Congress of the Osteoarthritis Research Society International (OARSI); December 8-11, 2005; Boston, Mass. Abstract P294.
Friday Jan 13, 2006
Increases in the Synthesis and Degradation of CTX-II Biomarkers May Predict OA Progression
Biomarkers of type II collagen synthesis and degradation may predict rapid progression among patients with knee osteoarthritis... Garnero P, et al. Presented at: 10th World Congress of the Osteoarthritis Research Society International (OARSI); December 8-11, 2005; Boston, Mass. Abstract A6.
Thursday Jan 05, 2006
New Study Suggests Raloxifene May Benefit Women with Knee Osteoarthritis
A recent study of women with knee osteoarthritis (OA) found that treatment with raloxifene resulted in a statistically significant decrease in the excretion of key markers of cartilage degradation, pointing to the potential curative effect of this agent and long-term improved outcomes for patients with knee OA... Daniluk S, et al. Presented at: 10th World Congress of the Osteoarthritis Research Society International (OARSI); December 8–11, 2005; Boston, Mass. Abstract P67.
Wednesday Jan 04, 2006
Oral Calcitonin May Delay Onset of Joint Disease and Relieve Pain of OA
Although calcitonin is an established antiresorptive agent, new research suggests that it also has a role in chondroprotection and may help relieve symptoms accompanying joint disease... Sondergaard BC, et al. Presented at: 10th World Congress of the Osteoarthritis Research Society International (OARSI); December 8–11, 2005; Boston, Mass. Abstract P133.
Wednesday Jan 04, 2006
Synta to Advance Clinical Development of IL-12/IL-23 Inhibitor for Crohn's Disease and RA
Synta Pharmaceuticals of Lexington, Massachusetts, announced that it will focus its clinical development efforts in 2006 on STA-5326, an oral interleukin (IL)-12/IL-23 inhibitor...
Tuesday Jan 03, 2006
Several Potential Biomarkers May Help Predict the Development of Osteoarthritis
Osteoarthritis (OA) has been found to be associated with changes in the serum proteins implicated in matrix degradation, cellular activation, and inflammation—changes that can occur years before radiographic detection of the disease... Ling SM, et al. Presented at: 10th World Congress of the Osteoarthritis Research Society International (OARSI); December 8–11, 2005; Boston, Mass. Abstract P51.
Tuesday Dec 20, 2005
KineMed Develops Assays for In Vivo Measurements of Cell and Matrix Molecule Turnover in OA
KineMed, Inc, of Emeryville, California, has announced that its proprietary stable isotope labeling and ultrasensitive mass spectrometry techniques have enabled researchers to measure cell proliferation...
Tuesday Dec 13, 2005
Research Points to the Importance of Diurnal Variations in Biomarkers for OA Assessment
A recent assessment of a cohort of patients with radiographic knee osteoarthritis uncovered substantial variations in the serum concentrations of key biomarkers of disease activity throughout the morning hours, changes that may affect clinical assessment of disease progression …. Kong SY, et al. Presented at: 10th World Congress of the Osteoarthritis Research Society International (OARSI); December 8–11, 2005; Boston, Mass. Abstract A8.
Wednesday Nov 16, 2005
TNF-α Antagonist Adalimumab Shows Promise in AS
Encouraging results from the ATLAS trial suggest that adalimumab and other TNF-α inhibitors may be effective in reducing the signs and symptoms of ankylosing spondylitis... Presented at: Annual Meeting of the American College of Rheumatology; November 12–17, 2005; San Diego, Calif.
Friday Oct 07, 2005
Marked Decrease in Pregnancy Loss Seen in Women with Lupus
Largely due to improvements in perinatal monitoring and disease management, there has been a significant decrease in pregnancy loss among women with systemic lupus erythematosus over the past 40 years . . . Clark CA, et al. J Rheumatol. 2005;32:1709-1712.
Tuesday Sep 27, 2005
Novel Method of Upfront Loading of Bisphosphonates Found to Improve Spinal Bone Mineral Density and Reduce Fractures
Upfront loading of oral or intravenous bisphosphonates followed by maintenance dosing may enhance the ability of these agents to reduce fracture risk compared with currently used dosing regimens... Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23-27, 2005; Nashville, Tennessee. Abstract M369.
Tuesday Sep 27, 2005
Researchers Report Promising Findings on Biomarkers for Postmenopausal Osteoporosis and OA
New research has uncovered biomarkers that serve as both diagnostic "fingerprints" for the risk of postmenopausal osteoporosis and predictors for osteoarthritis (OA) progression... Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23-27, 2005; Nashville, Tennessee.
Monday Sep 19, 2005
A Leading Rheumatologist Reflects on How Cyclooxygenase Became a Household Word
Just as it appeared that the dust from the great COX-2 controversies had begun to settle, a jury in Texas awarded a plaintiff a judgment against Merck & Co for one quarter of a billion dollars - indeed, for a death that, arguably, was not Vioxx-related.
Monday Aug 08, 2005
Velcura Receives $1.3 Million SBIR Grant for New Osteoporosis Drugs
Velcura Therapeutics®, Inc, a biotechnology company focused on developing drugs for bone diseases, received a $1.3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging, of the National Institutes of Health, to use proteomics-based drug discovery in human osteoblasts to identify bone disease biomarkers and targets, and develop new drugs that stimulate bone formation.
Friday Jun 17, 2005
Vertex Inhibitor of p38 MAP Kinase Starts Phase II in RA
Vertex Pharmaceuticals Inc has initiated a 3-month Phase II clinical trial of VX-702, an orally administered small molecule inhibitor of p38 mitogen-activated protein (MAP) kinase, for the treatment of rheumatoid arthritis (RA).
Thursday Jun 09, 2005
Study Helps Clarify Link Between RA and CVD
Il-6, rheumatoid factor, and chronic kidney disease predict endothelial dysfunction among RA patients and need to be suppressed to stave off atherosclerosis...Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Monday Apr 04, 2005
Analgesic Drug Pipeline, Though Relatively Dry, Poised for Revitalization
Despite a relative paucity in the current analgesic pipeline, a greater understanding of complex pain processes, pharmacogenetics, and new diagnostic tools and therapeutic targets, including assays and biomarkers, may open the doorway to more effective therapies, as well as better use of existing treatments...Presented at: 24th Annual Scientific Meeting of the American Pain Society; March 30-April 2, 2005; Boston, Mass.
Sunday Mar 20, 2005
Canada's NRC Funds ChondroGene to Support Development of OA Test
ChondroGene Limited of Toronto, Canada, has received financial support from the Canadian National Research Council's Industrial Research Assistance Program to further develop a blood-based test to stage osteoarthritis (OA) and to detect early, asymptomatic disease.
Monday Mar 14, 2005
Novel Estrogenic Agonist May Suppress Inflammation
Preclinical and Phase I data suggest that an estrogen receptor beta-agonist, ERB-041, may have potent anti-inflammatory properties without classic estrogenic effects...American College of Rheumatology 2005 Innovative Therapies in Autoimmune Disease Meeting, Washington, DC, March 4-6, 2005.
Sunday Mar 13, 2005
Markers of Systemic Inflammation May Be Independent Risk Factors for Cardiovascular Death in Patients With Rheumatoid Arthritis
A new study indicates that ESR may be predictive of CV mortality and suggests that tighter control of inflammation may help improve long-term outcomes for RA patients...Maradit-Kremers H, et al. Arthritis Rheum. 2005;52:722-732.
Thursday Feb 17, 2005
Anti-CCP Antibodies Detected in Psoriatic Arthritis Patients
New research suggests that the specificity of this marker may lead to more precise diagnostic criteria for this broad spectrum disease...Vander Cruyssen B, et al. Ann Rheum Dis. 2005. [Epub ahead of print]
Tuesday Sep 21, 2004
Potential Osteoarthritis Biomarker Found
Elevated levels of CTX-II, type II collagen-derived fragments, may be an indicator of the presence and progression of OA.
Monday Aug 30, 2004
SLE Researchers Encouraged to Use Biomarkers, Surrogate Markers as Study Endpoints; New Research Shows B-Cell Depletion to Have Role in SLE Therapy
(Schiffenbauer J, et al. Arthritis Rheum. 2004;50:2415-2422; Looney RJ, et al. Arthritis Rheum. 2004;50:2580-2589.)
|
